The Analyst Verdict: RxSight In The Eyes Of 9 Experts

9 analysts have expressed a variety of opinions on RxSight RXST over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.0, a high estimate of $66.00, and a low estimate of $28.00. This current average has decreased by 15.49% from the previous average price target of $47.33.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive RxSight is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RxSight. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RxSight compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of RxSight's stock. This comparison reveals trends in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of RxSight's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on RxSight analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know RxSight Better

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Financial Milestones: RxSight's Journey

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: RxSight's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 40.71%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: RxSight's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -14.77%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): RxSight's ROE stands out, surpassing industry averages. With an impressive ROE of -2.13%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): RxSight's ROA excels beyond industry benchmarks, reaching -1.89%. This signifies efficient management of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.